In last trading session, the stock price of Propanc Health Group Corp (OTCMKTS:PPCH) surged more than 16% to close the day at $0.0420. The gains came at a share volume of 40.82 million compared to average share volume of 13.36 million.
Propanc Health reported that it had filed for two patent applications in the U.S. pertaining to new compositions of PRP for treating cancer. The new composition summarize different blends of the two proenzymes, chymotrypsinogen and trypsinogen, which synergistically improve their anti-cancer effects, against when used as singular agents or in a one to one ratio. These compositions are in addition to the favored combination for PRP, and enhances the company’s patent role across a broad group of cancers.
Propanc Health plans to meet with the MHRA to talk on clinical and preclinical development programs for PRP. The management intends to file for orphan drug status for ovarian and pancreatic cancers in the EU and US in the near future, in case they fulfill the necessary criteria. Propanc also plans to fast track the advancement of proenzyme based oncology products into clinical studies initially for ovarian and pancreatic cancers, and later for colorectal cancer.
The management view
Dr Julian Kenyon, the CSO of Propanc, said that while confirming PRP’s effectiveness for different types of cancers, they also assessed a synergistic response in between the proenzymes to most of cancer cell lines. They recorded that for certain cancer types, over one combination showed to be effective, which the team believe is patentable.
It is an important development because it confirms the utility of PRP for numerous cancers, and enables them to use other effective combinations. Propanc now have 5 individual patents and also project to submit further divisional applications in several jurisdictions. The management is extremely delighted with progress as they advance a strong portfolio as pioneers in the field.